HCA · NYSE · STOCK
HCA Healthcare (HCA) Stock Analysis
$451.17
52W $353.99 – $556.52
57/100
$97.66B
15.1
1.11
Is HCA Bullish or Bearish?
Bullish.
Innellis AI committee rates HCA Healthcare (HCA) Buy with a composite score of 57/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +18.47 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -1.53 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 25.5% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 14.2 is inexpensive for the broad market — Value
- ROE of 695.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.5% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 97.3x prices in significant intangible value — Value
- Debt-to-equity of 54.20 adds balance-sheet risk to the value case — Value
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- High leverage (debt-to-equity 54.20) amplifies downside in a stress scenario — Risk
- Current ratio of 0.97 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 54%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ P/E of 14.2 is inexpensive for the broad market
− Price-to-book of 97.3x prices in significant intangible value
Growth Analyst
bullish
70
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 25.5% YoY
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 73 is in overbought territory
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 54.20) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
63
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.17 across 12 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 58.1 to 56.5.
- Conviction changed from moderate to contested.
- Committee agreement fell notably from 67% to 50%.
- New bearish signals: 1 appeared.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 2 appeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Technical Analyst: stance bullish->neutral; score 61->54 (-8); +1 bearish signal(s).
- Value Analyst: +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
73.2
Overbought
MACD Histogram
1.312
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$397.46
Resistance
$519.67
Bollinger %B
1.15
Above Upper Band
Price vs Moving Averages
EMA 9
$437.80
Above
EMA 21
$431.45
Above
EMA 50
$422.46
Above
EMA 200
$426.24
Above
Fundamental Analysis
Valuation
100
Growth
75
Profitability
41
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
15.1×
P/B Ratio
-15.29×
PEG Ratio
0.62
Dividend Yield
0.68%
52W High
$556.52
52W Low
$353.99
Quality & Growth
ROE
-11256.0%
ROA
1117.3%
Gross Margin
2835.5%
Operating Margin
1547.6%
Revenue Growth YoY
—
Debt / Equity
-7.42
AI Fundamental Assessment
P/E ratio of 15.1 (inexpensive relative to a 15-40x range); Price-to-book of -15.3x; PEG ratio of 0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -112.6%; Return on assets of 11.2%; Net margin of 8.8%; Gross margin of 28.4%; Current ratio of 0.78 (tight short-term liquidity); Debt-to-equity of -7.42; Free cash flow per share is positive (26.91); Most recent quarter beat estimates by 1.0%; EPS growth accelerating (-12.2% -> +6.6% QoQ); Average YoY EPS growth of 11.6%; Analyst estimates flat over recent quarters
Get the Full HCA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →